Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TH-4000 |
Synonyms | |
Therapy Description |
TH-4000 (tarloxotinib) is a prodrug that is converted to an irreversible Egfr/Erbb2 (Her2)/Erbb4 inhibitor under hypoxia, potentially resulting in inhibition of tumor cell growth (PMID: 33355298). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TH-4000 | PR610|Hypoxin|TRLX|Tarloxotinib bromide|Tarloxotinib | EGFR Inhibitor (Pan) 65 HER2 Inhibitor 43 | TH-4000 (tarloxotinib) is a prodrug that is converted to an irreversible Egfr/Erbb2 (Her2)/Erbb4 inhibitor under hypoxia, potentially resulting in inhibition of tumor cell growth (PMID: 33355298). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02454842 | Phase II | TH-4000 | Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC | Terminated | USA | AUS | 0 |
NCT03805841 | Phase II | TH-4000 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) | Terminated | USA | CAN | 1 |
NCT01631279 | Phase Ib/II | TH-4000 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | Terminated | USA | NZL | 0 |
NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |